DemeRx Inc. is developing ibogaine based treatments for opioid abuse. The company plans to advance ibogaine for opioid detoxification in medically-supervised inpatient settings as well as use Noribogaine as a low-dose adjunct therapy for patients in early recovery among other conditions.
In January 2020, the company announced that it received an investment in two joint ventures from ATAI Life Sciences AG, totaling $22 million to help advance its ibogaine-based treatment options.
Management Team
Richard Serbin
Executive Chairman
Deborah Mash, Ph.D.
Founder & CEO
Michael Karukin, Ph.D.
Chief Operating Officer
Pascal Goldschmidt, MD, FACC, FAHA
Chief Medical Officer
John Thomas CPA
Chief Financial Officer